Digest Network Come funziona
Network
/
Società
Nu
Non verificato

Nuvation Bio

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

17 comunicati stampa

Guarda tutti i comunicati
12/01/2026
Web e Social Network
Finanza
Eventi
Mercato azionario
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Igiene alimentare
Medicina - Varie
Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference
Fonte
Nuvation Bio
Emittente
Business Wire
1.00
0
06/01/2026
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
Eventi
Web e Social Network
Nuvation Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference
Fonte
Nuvation Bio
Emittente
Business Wire
1.00
0
03/12/2025
Industria
Scienza
Igiene alimentare
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Oncologia
Nuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 IDH1-Mutant Glioma in Neuro-Oncology
Fonte
Nuvation Bio
Emittente
Business Wire
1.00
0
26/11/2025
Oncologia
Salute
Scienza
Farmaceutica
Biotecnologia
Eventi
Web e Social Network
Nuvation Bio to Participate in Upcoming Investor Conferences
Fonte
Nuvation Bio
Emittente
Business Wire
1.00
0
30/10/2025
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
Web e Social Network
Eventi
Nuvation Bio to Participate in Upcoming Investor Conferences
Fonte
Nuvation Bio
Emittente
Business Wire
1.00
0
23/10/2025
Industria
Scienza
Igiene alimentare
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Oncologia
Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma
Fonte
Nuvation Bio
Emittente
Business Wire
1.00
0
20/10/2025
Scienza
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Nuvation Bio to Report Third Quarter 2025 Financial Results and Provide Business Update on November 3, 2025
Fonte
Nuvation Bio
Emittente
Business Wire
1.00
0
30/09/2025
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Industria
Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI™ (taletrectinib) for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer
Fonte
Nuvation Bio
Emittente
Business Wire
1.00
0
19/09/2025
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Industria
Nuvation Bio Receives Approval from Japan’s Ministry of Health, Labour and Welfare for IBTROZITM for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer
Fonte
Nuvation Bio
Emittente
Business Wire
1.00
0
07/09/2025
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Eventi
Industria
Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer
Fonte
Nuvation Bio
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0